As of 2025-06-20, the Intrinsic Value of Rubius Therapeutics Inc (RUBY) is -14.47 USD. This RUBY valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.08 USD, the upside of Rubius Therapeutics Inc is -17,533.68%.
Based on its market price of 0.08 USD and our intrinsic valuation, Rubius Therapeutics Inc (RUBY) is overvalued by 17,533.68%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -14.47 - -14.47 | -14.47 | -17,533.68% |
| P/E | (70.03) - (81.15) | (83.93) | -101215.3% |
| DDM - Stable | (15.88) - (49.54) | (32.71) | -39512.6% |
| DDM - Multi | (12.48) - (32.79) | (18.37) | -22228.9% |
| Market Cap (mil) | 5.15 |
| Beta | 4.04 |
| Outstanding shares (mil) | 62.08 |
| Enterprise Value (mil) | -9.75 |
| Market risk premium | 4.60% |
| Cost of Equity | 13.01% |
| Cost of Debt | 5.00% |
| WACC | 8.34% |